The global wearable injectors market is projected to reach USD 21.0 billion in 2031, up from USD 12.6 billion in 2026, at a CAGR of 10.8% during the forecast period.
The wearable injectors market is primarily driven by several key factors. Key factors fueling market growth include growing preference for home healthcare and self-administration, rising R&D activity and strategic partnerships, and the use of artificial intelligence in diabetes management devices. Globally, there has been a marked increase in the prevalence of chronic illnesses such as diabetes, cancer, and cardiovascular diseases. This trend, coupled with a growing geriatric population, is fueling the growth of the wearable injectors market. Moreover, the rising incidence of chronic conditions has increased demand for home care treatments, which are essential to improving patient compliance and outcomes. This shift toward home healthcare underscores the need for innovative wearable injectors that serve a diverse patient population while ensuring optimal therapeutic management. Emerging markets such as India, Brazil, and Southeast Asia present lucrative opportunities in this market. However, the high cost of wearable injectors and stringent regulatory requirements limit market growth to some extent.
To know about the assumptions considered for the study download the pdf brochure
Prominent players offering wearable injector devices include Medtronic (Ireland), BD (US), West Pharmaceutical Services, Inc. (US), Gerresheimer AG (Germany), and Insulet Corporation (US). Prominent players offering wearable injector formulations include Amgen Inc. (US), AbbVie Inc. (US), United Therapeutics Corporation (US), Apellis Pharmaceuticals, Inc. (US), and Supernus Pharmaceuticals, Inc. (US). These companies have implemented a variety of growth strategies, both organic and inorganic, including introducing new products, forming strategic partnerships and entering emerging markets. These initiatives are aimed at enhancing their market share and diversifying their portfolios.
In April 2025, Medtronic received the US FDA approval for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system offers more flexibility for users of the company's advanced insulin delivery system featuring Meal Detection technology with the Guardian 4 sensor and Simplera Sync sensor.
In January 2026, LTS Device Technologies collaborated with Stevanato Group and Datwyler to expand on-body delivery options for large-volume drugs. The collaboration combines LTS's wearable device technology with drug-containment and elastomer-component capabilities to support subcutaneous administration of higher-dose therapies, including monoclonal antibodies and anticancer treatments.
In January 2026, West Pharmaceutical Services announced an agreement to transfer the manufacturing and supply rights for its SmartDose 3.5 mL on-body delivery system and associated facilities to AbbVie for USD 112.5 million. West completed the transaction in July 2026 and retained its development and manufacturing activities for other SmartDose configurations, including the 10 mL platform.
Medtronic (Ireland)
Medtronic is a medical technology company that offers a wide range of innovative products and therapies to treat more than 30 chronic diseases, including cardiac, diabetic, neurological, and spinal conditions. The company operates in four segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company offers wearable injectors under the Diabetes business segment. Recognized for its commitment to innovation, Medtronic has established a robust presence in the US, Europe, and Japan; its manufacturing & research facilities are located in the US, Puerto Rico, Canada, France, Germany, Ireland, Israel, Italy, and Mexico. Medtronic has used both organic growth and strategic acquisitions to strengthen its market position.
AbbVie Inc. (US)
AbbVie Inc. is a leading research-oriented biopharmaceutical company that develops and markets innovative products used in therapeutic areas, such as oncology, chronic autoimmune diseases, virology, and neurological disorders. The company offers its drugs in immunology, neuroscience, virology, general medicine, eye care, aesthetics, and oncology. The company offers its wearable injector, SKYRIZI, in the Immunology therapeutic area. It has a significant global footprint in over 70 countries, with 22 R&D facilities distributed worldwide.
Market Ranking:
The wearable injectors market is divided into device manufacturers and formulation providers.
The top five companies offering wearable injector devices are Insulet Corporation (US), Medtronic (Ireland), Tandem Diabetes Care, Inc. (US), BD (US), and West Pharmaceutical Services, Inc. (US). These companies have established strong positions through innovation in wearable design, delivery efficiency, and patient-centric features. Insulet Corporation (US), widely recognized for its Omnipod system, dominates in pump-based automated insulin delivery (AID) technologies. Medtronic (Ireland) leads with an extensive medical technology portfolio and is actively investing in miniaturized, smart wearable systems for diabetes management. Tandem Diabetes Care, Inc. (US) focuses on integration of digital health, remote monitoring, and IoT with wearable insulin injectors. BD (US) has leveraged its expertise in injection technologies and integrated solutions to develop large-volume and user-friendly wearable injectors with advanced safety features. West Pharmaceutical Services, Inc. (US) stands out for its proprietary wearable platforms and collaborations with biopharma companies to support subcutaneous biologic delivery.
The top five companies offering wearable injector formulations are Amgen Inc. (US), AbbVie Inc. (US), United Therapeutics Corporation (US), Apellis Pharmaceuticals, Inc. (US), and Supernus Pharmaceuticals, Inc. (US). These companies have developed or partnered to commercialize biologics and specialty drugs designed for subcutaneous self-administration via wearable platforms. Amgen (US) has pioneered self-administered biologic therapies with on-body devices like the Neulasta Onpro kit. AbbVie (US) supports wearable delivery with SKYRIZI, indicated for moderate to severe plaque psoriasis, and is investing in patient-adherence-focused drug-device combinations. United Therapeutics Corporation (US) focuses on wearable systems like Remodulin, a prescription medication used to treat adults with pulmonary arterial hypertension and improve quality of life. Apellis Pharmaceuticals, Inc. (US) and Supernus Pharmaceuticals, Inc. (US) are advancing long-acting therapies and neurology-focused formulations, respectively, designed for compatibility with wearable injectors to improve patient outcomes in chronic treatment settings.
Related Reports:
Wearable Injectors Market by Product (On-body/Off-body), Technology (Spring, Motor Driven, Rotary Pump), Usage (Disposable, Reusable), Delivery Method (Bolus, Programmed Infusion), Therapeutic Application (Diabetes, Oncology) - Global Forecast to 2031
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE